Combined orthotopic heart and liver transplantation: the need for exception status listing.

Through May 2004, 33 combined orthotopic heart-liver transplants (OHT/OLT) have been performed nationwide. No published data exist to date regarding outcomes of patients awaiting such transplants, although progression of two organ disease processes may contribute to premature death for waiting patients. Retrospective data were collected on patients listed for combined OHT/OLT from both an individual tertiary care transplant center and the national UNOS registry to delineate listing criteria and evaluate patient outcomes in both the pre- and post-MELD eras. All patients who survived to transplantation or died on the waiting list were included in the analysis. Results show that 29.6% of patients registered nationally and 42% of patients listed institutionally survived to transplantation. Survival to transplantation was associated with less severe liver disease, though patients with MELD scores ranging from 19 to 26 had significantly higher wait list mortality than expected when compared to single-organ liver transplants. Following combined orthotopic heart-liver transplantation, 80% and 70% of patients survive 1 and 3 years, respectively. In conclusion, combined OHT/OLT is a successful therapy, but current organ allocation policies may not ensure expeditious transplantation in critically ill patients with dual vital organ failure. Providing exception status listing to these patients would ensure more expeditious transplantation and potentially contribute to improved survival.

A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home.

BACKGROUND: We performed a prospective study to determine the feasibility and safety of continuous intravenous milrinone therapy administered at home in patients listed as Status IB for heart transplant. METHODS: Patients who were Status IB could participate if they met specific criteria including an optimal dose of milrinone < or =0.5 microg/kg/min, presence of an implantable cardioverter-defibrillator (ICD), and no other serious comorbidity. The primary end-point of the study was survival to transplant. Hospitalizations, quality of life and cost comparisons were assessed. RESULTS: From May 1999 through October 2002, a total of 60 patients (51 men, 9 women), aged 55.5 +/- 8.4 years, entered the study. Before milrinone therapy, cardiac index was 1.98 +/- 0.66 liters/min/m2 and peak oxygen consumption was 11.4 +/- 2.6 ml/kg/min. Mean time in the study was 160.1 +/- 151.8 days. Fifty-three patients (88.3%) underwent heart transplant. There were only 2 deaths during the study. There were 89 hospital admissions in 46 patients over the 43-month follow-up period; 58 of these admissions were for heart failure. There were 6 episodes of ICD firing for ventricular tachycardia. Quality-of-life measures in a sub-group of patients significantly improved 1 month after discharge. Substantial estimated cost savings occurred. CONCLUSIONS: Continuous intravenous milrinone therapy can be safely administered at home in selected patients with advanced heart failure who are listed for transplant. This strategy may be an acceptable alternative to prolonged hospitalization for patients dependent on continuous inotropic support. Re-hospitalization is to be expected. An implantable cardioverter-defibrillator should be present due to the incidence of ventricular tachycardia.

Diaphragmatic hernias associated with ventricular assist devices and heart transplantation.

BACKGROUND: Diaphragmatic hernias in heart transplant recipients with prior left ventricular assist device (LVAD) placement are a potentially life-threatening complication. This review examined the incidence, diagnostic strategies, surgical management, and prevention of diaphragmatic hernias in these patients. METHODS: A retrospective review of patients receiving a Thoratec HeartMate (Thoratec Laboratories Corp, Pleasanton, CA) LVAD who developed a diaphragmatic hernia after VAD explantation and orthotopic heart transplantation (OHT). Two groups were identified and their results compared. In the early group, the diaphragmatic defect was not closed at the time of OHT and VAD explantation, while in the late group the defect was closed. RESULTS: In the early group, between September 1995 and November 1999, a total of 61 HeartMate LVADs were placed intraperitoneally as a bridge to transplantation, and 44 of those patients went on to OHT. Of these patients, 7 of 44 (15.9%) developed a diaphragmatic hernia after transplantation. Five of the patients underwent successful surgery by laparotomy without recurrence. Two patients with asymptomatic diaphragmatic hernia await repair. After a modification in diaphragmatic closure after VAD explantation at the time of OHT, in the late group between November 1999 and July 2002, 29 HeartMate LVADs were placed and 23 patients went on to OHT. There has been one diaphragmatic hernia (1 of 23, 4.3%) in this group. CONCLUSIONS: Diaphragmatic hernia following VAD placement and heart transplantation requires an aggressive diagnostic and therapeutic approach in this immunosuppressed patient population. We recommend primary closure of all diaphragmatic defects at the time of OHT and VAD explantation to reduce the incidence of this complication.

Successful explantation of a ventricular assist device following fulminant influenza type A-associated myocarditis.

We report a case of fulminant myocarditis associated with refractory ventricular fibrillation following influenza A infection. Histologic examination was consistent with myocarditis and serology confirmed the viral etiology. The patient was supported with biventricular assist devices for 20 days during which her refractory ventricular fibrillation resolved spontaneously. This is the first documented case of resolution of prolonged ventricular fibrillation while on a ventricular assist device. This case suggests those patients with fulminant viral myocarditis and refractory ventricular arrhythmias may be supported successfully with ventricular assist devices until myocardial recovery takes place.